prednisolone and Pain studies

Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.

Pain: An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.

Research Excerpts

Excerpt	Relevance	Reference
"Biomarkers reflecting tissue turnover and inflammation [aggrecanase-derived neoepitope of arggecan (ARGS), MMP-derived neoepitope of type I collagen (C1M), MMP-derived neoepitope of type III collagen (C3M), marker of true type V collagen formation (PROC5), MMP-derived neoepitope of CRP (CRPM), citrullinated vimentin fragment (VICM), high-sensitivity (hsCRP)] were measured in sera from 78 patients with painful inflammatory hand OA, who were randomized between prednisolone or placebo treatment."	9.69	Serum biomarkers in prednisolone-treated hand osteoarthritis patients. ( Bay-Jensen, AC; Kloppenburg, M; Kroon, FPB; Thudium, CF; van de Stadt, LA, 2023)
"This pragmatic, prospective, double-blind, double-dummy, parallel-group, randomized, non-inferiority trial investigates whether prednisolone (intervention) is non-inferior to treatment with colchicine (active control) in patients with acute gout."	9.69	Prednisolone Versus Colchicine for Acute Gout in Primary Care (COPAGO): protocol for a two-arm multicentre, pragmatic, prospective, randomized, double-blind, controlled clinical trial of prednisolone and colchicine for non-inferiority with a parallel grou ( Böhm, S; Bülow, R; Chenot, JF; Dörr, M; Engeli, S; Freyer Martins Pereira, J; Gágyor, I; Greser, A; Hummers, E; Kamin, P; Richter, A; Schuster, F; Stracke, S; Truthmann, J; Witte, A, 2023)
"Data were analysed from a 6-week, randomized, double-blind, placebo-controlled trial investigating prednisolone treatment in 92 patients with painful inflammatory hand OA."	9.51	Neuropathic-like pain symptoms in inflammatory hand osteoarthritis lower quality of life and may not decrease under prednisolone treatment. ( Allaart, CF; Böhringer, S; Boonen, AERCH; Kloppenburg, M; Kortekaas, MC; Kroon, FPB; Niesters, M; Reijnierse, M; Riyazi, N; Rosendaal, FR; Starmans-Kool, M; Turkstra, F; van de Stadt, LA; van der Meulen, C; van Zeben, J, 2022)
"To compare the effectiveness and safety of oral prednisolone versus oral indomethacin in patients presenting to emergency departments (EDs) with acute gout."	9.22	Oral Prednisolone in the Treatment of Acute Gout: A Pragmatic, Multicenter, Double-Blind, Randomized Trial. ( Cheng, CH; Choi, YF; Graham, CA; Janssens, HJ; Lee, KH; Man, CY; Rainer, TH; Tam, LS; Yau, WH, 2016)
"Prednisolone and/or valacyclovir did not affect the incidence or intensity of ipsilateral pain in Bell's palsy."	9.14	The course of pain in Bell's palsy: treatment with prednisolone and valacyclovir. ( Axelsson, S; Berg, T; Engström, M; Jonsson, L; Kanerva, M; Pitkäranta, A; Stjernquist-Desatnik, A, 2009)
"Bucillamine (Buc), developed in Japan, is a disease-modifying antirheumatic drug (DMARD) which has been used to treat numerous patients with rheumatoid arthritis (RA) in Japan and Korea with favorable results."	9.14	A comparative study of the effects of bucillamine and salazosulfapyridine in the treatment of rheumatoid arthritis. ( Abe, M; Kinoshita, M; Nakajima, M; Ohara, H; Ueda, N, 2009)
"The results of this study suggest that SKI306X was generally well tolerated and not inferior to celecoxib in regard to pain relief in these Korean patients with RA."	9.12	Assessment of comparative pain relief and tolerability of SKI306X compared with celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, double-dummy, phase III, noninferiority clinical trial. ( Baek, HJ; Cha, HS; Jung, HG; Kang, SW; Kim, HA; Koh, EM; Lee, CK; Lee, EY; Lee, YJ; Song, YW; Suh, Y; Yoo, B, 2007)
"Bucillamine (Buc) is a disease-modifying antirheumatic drug (DMARD) developed in Japan, which has been used as one of the first-line DMARDs for the treatment of rheumatoid arthritis (RA) in Japan."	9.12	Efficacy profile of bucillamine in rheumatoid arthritis patients in a large observational cohort study, IORRA. ( Hara, M; Inoue, E; Iwatani, M; Kamatani, N; Nakajima, A; Nakamura, T; Tomatsu, T; Yamanaka, H, 2006)
"Indomethacin, 100 mg orally, was compared with prednisolone, 5 mg, as addititional therapy at night, in a two-week, double-blind, between-patient study in twenty-four in-patients with rheumatoid arthritis."	9.04	Indomethacin or prednisolone at night in rheumatoid arthritis? ( Murthy, MH; Rhymer, AR; Wright, V, 1978)
"Prednisolone in low doses (< or = 15 mg daily) may be used intermittently in patients with rheumatoid arthritis, particularly if the disease cannot be controlled by other means."	8.80	Meta-analysis of short-term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. ( Gøtzsche, PC; Johansen, HK, 1998)
"Severe hyponatremia is rare when carbamazepine is used as monotherapy."	7.88	Walking hyponatremia syndrome of inappropriate antidiuretic hormone secretion secondary to carbamazepine use: a case report. ( Palacios Argueta, PJ; Pineda, A; Sánchez Rosenberg, GF, 2018)
"Adhesive capsulitis or frozen shoulder is a common condition characterized by shoulder pain and stiffness in which conservative methods of treatment such as glucocorticosteroids, anti-inflammatory drugs, and physiotherapy play a significant part."	6.73	Pain relieving effect of short-course, pulse prednisolone in managing frozen shoulder. ( Haghighi, MH; Hemmati, AA; Saeidian, SR, 2007)
"Pamidronate treatment also did not have any influence on patient survival or on the frequency of hypercalcaemia."	6.69	Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group. ( Abildgaard, N; Brincker, H; Ford, J; Gimsing, P; Hedenus, M; Kandra, A; Turesson, I; Westin, J, 1998)
"This pragmatic, prospective, double-blind, double-dummy, parallel-group, randomized, non-inferiority trial investigates whether prednisolone (intervention) is non-inferior to treatment with colchicine (active control) in patients with acute gout."	5.69	Prednisolone Versus Colchicine for Acute Gout in Primary Care (COPAGO): protocol for a two-arm multicentre, pragmatic, prospective, randomized, double-blind, controlled clinical trial of prednisolone and colchicine for non-inferiority with a parallel grou ( Böhm, S; Bülow, R; Chenot, JF; Dörr, M; Engeli, S; Freyer Martins Pereira, J; Gágyor, I; Greser, A; Hummers, E; Kamin, P; Richter, A; Schuster, F; Stracke, S; Truthmann, J; Witte, A, 2023)
"Biomarkers reflecting tissue turnover and inflammation [aggrecanase-derived neoepitope of arggecan (ARGS), MMP-derived neoepitope of type I collagen (C1M), MMP-derived neoepitope of type III collagen (C3M), marker of true type V collagen formation (PROC5), MMP-derived neoepitope of CRP (CRPM), citrullinated vimentin fragment (VICM), high-sensitivity (hsCRP)] were measured in sera from 78 patients with painful inflammatory hand OA, who were randomized between prednisolone or placebo treatment."	5.69	Serum biomarkers in prednisolone-treated hand osteoarthritis patients. ( Bay-Jensen, AC; Kloppenburg, M; Kroon, FPB; Thudium, CF; van de Stadt, LA, 2023)
"This randomized double-blinded trial aimed to compare the anesthetic success of inferior alveolar nerve blocks (IANBs) with 2% lidocaine in mandibular molars with symptomatic irreversible pulpitis (SIP) after oral premedication of prednisolone, dexamethasone, and ketorolac with placebo."	5.69	Effect of Preoperative Oral Steroids in Comparison to Anti-inflammatory on Anesthetic Success of Inferior Alveolar Nerve Block in Mandibular Molars with Symptomatic Irreversible Pulpitis-A Double-blinded Randomized Clinical Trial. ( Hegde, V; Kulkarni, V; Nagendrababu, V; Setzer, FC; Shaikh, S; Shanmugasundaram, S; Suresh, N, 2023)
"KEY MESSAGESLow initial dose (15 mg/d) of prednisolone was non-inferior to the standard initial dose of prednisolone (30 mg/d) in treatment duration, time to pain relief, or the prevalence of hypothyroidism, recurrence, and adverse reactions in the treatment of subacute thyroiditis."	5.69	Comparison of the therapeutic effects of 15 mg and 30 mg initial daily prednisolone doses in patients with subacute thyroiditis: a multicenter, randomized, open-label, parallel-controlled trial. ( Gao, B; Gao, L; Jia, A; Jiao, Y; Jing, X; Shang, L; Wang, J; Xing, Y; Xu, J; Xu, S; Xu, W; Zeng, J; Zhang, J, 2023)
"Data were analysed from a 6-week, randomized, double-blind, placebo-controlled trial investigating prednisolone treatment in 92 patients with painful inflammatory hand OA."	5.51	Neuropathic-like pain symptoms in inflammatory hand osteoarthritis lower quality of life and may not decrease under prednisolone treatment. ( Allaart, CF; Böhringer, S; Boonen, AERCH; Kloppenburg, M; Kortekaas, MC; Kroon, FPB; Niesters, M; Reijnierse, M; Riyazi, N; Rosendaal, FR; Starmans-Kool, M; Turkstra, F; van de Stadt, LA; van der Meulen, C; van Zeben, J, 2022)
"In these prespecified exploratory analyses, there was no significant difference in pain or HRQOL when olaparib was added to abiraterone."	5.51	Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial. ( Alekseev, B; Burgents, J; Chiuri, VE; Clarke, NW; Degboe, A; Fléchon, A; Gresty, C; Jassem, J; Jones, R; Kang, J; Kocak, I; Redfern, C; Saad, F; Sala, N; Thiery-Vuillemin, A; Wiechno, P, 2022)
"In type I Gaucher's disease, episodes of severe disabling bone pain, the so called bone crises, may be resistant to all analgesics, including narcotics."	5.29	Effective treatment of painful bone crises in type I gaucher's disease with high dose prednisolone. ( Cohen, IJ; Katz, K; Kornreich, L; Mekhmandarov, S; Zaizov, R, 1996)
"To compare the effectiveness and safety of oral prednisolone versus oral indomethacin in patients presenting to emergency departments (EDs) with acute gout."	5.22	Oral Prednisolone in the Treatment of Acute Gout: A Pragmatic, Multicenter, Double-Blind, Randomized Trial. ( Cheng, CH; Choi, YF; Graham, CA; Janssens, HJ; Lee, KH; Man, CY; Rainer, TH; Tam, LS; Yau, WH, 2016)
"Prednisolone and/or valacyclovir did not affect the incidence or intensity of ipsilateral pain in Bell's palsy."	5.14	The course of pain in Bell's palsy: treatment with prednisolone and valacyclovir. ( Axelsson, S; Berg, T; Engström, M; Jonsson, L; Kanerva, M; Pitkäranta, A; Stjernquist-Desatnik, A, 2009)
"Bucillamine (Buc), developed in Japan, is a disease-modifying antirheumatic drug (DMARD) which has been used to treat numerous patients with rheumatoid arthritis (RA) in Japan and Korea with favorable results."	5.14	A comparative study of the effects of bucillamine and salazosulfapyridine in the treatment of rheumatoid arthritis. ( Abe, M; Kinoshita, M; Nakajima, M; Ohara, H; Ueda, N, 2009)
"To test a new drug for patients with recurrent oral aphthae nonresponsive to local corticosteroid therapy, we compared the therapeutic effectiveness and adverse effects of systemic prednisone and systemic montelukast in a placebo-controlled trial."	5.14	Pilot study on recurrent aphthous stomatitis (RAS): a randomized placebo-controlled trial for the comparative therapeutic effects of systemic prednisone and systemic montelukast in subjects unresponsive to topical therapy. ( Buonaiuto, C; Cirillo, N; Femiano, F; Gombos, F; Lanza, A, 2010)
"Bucillamine (Buc) is a disease-modifying antirheumatic drug (DMARD) developed in Japan, which has been used as one of the first-line DMARDs for the treatment of rheumatoid arthritis (RA) in Japan."	5.12	Efficacy profile of bucillamine in rheumatoid arthritis patients in a large observational cohort study, IORRA. ( Hara, M; Inoue, E; Iwatani, M; Kamatani, N; Nakajima, A; Nakamura, T; Tomatsu, T; Yamanaka, H, 2006)
"The results of this study suggest that SKI306X was generally well tolerated and not inferior to celecoxib in regard to pain relief in these Korean patients with RA."	5.12	Assessment of comparative pain relief and tolerability of SKI306X compared with celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, double-dummy, phase III, noninferiority clinical trial. ( Baek, HJ; Cha, HS; Jung, HG; Kang, SW; Kim, HA; Koh, EM; Lee, CK; Lee, EY; Lee, YJ; Song, YW; Suh, Y; Yoo, B, 2007)
"To compare the effectiveness of a steroid injection (25 mg/ml prednisolone acetate) with a local anaesthetic control in the treatment of heel pain and to determine any advantage for patients' comfort of using a posterior tibial nerve block to anesthetize the heel prior to infiltration."	5.09	Steroid injection for heel pain: evidence of short-term effectiveness. A randomized controlled trial. ( Atkins, D; Crawford, F; Edwards, J; Young, P, 1999)
"Prednisolone reduced the progression of joint destruction over 2 yr in early, active rheumatoid arthritis."	5.08	Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. ( Hickling, P; Jacoby, RK; Kirwan, JR, 1998)
"Both prednisolone and papase are effective in reducing the oral surgical sequelae of trismus and pain, although prednisolone apparently is the more potent drug."	5.04	Double-blind study of prednisolone and papase as inhibitors of complications after oral surgery. ( Caci, F; Gluck, GM, 1976)
"Indomethacin, 100 mg orally, was compared with prednisolone, 5 mg, as addititional therapy at night, in a two-week, double-blind, between-patient study in twenty-four in-patients with rheumatoid arthritis."	5.04	Indomethacin or prednisolone at night in rheumatoid arthritis? ( Murthy, MH; Rhymer, AR; Wright, V, 1978)
"Prednisolone in low doses (< or = 15 mg daily) may be used intermittently in patients with rheumatoid arthritis, particularly if the disease cannot be controlled by other means."	4.80	Meta-analysis of short-term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. ( Gøtzsche, PC; Johansen, HK, 1998)
"Severe hyponatremia is rare when carbamazepine is used as monotherapy."	3.88	Walking hyponatremia syndrome of inappropriate antidiuretic hormone secretion secondary to carbamazepine use: a case report. ( Palacios Argueta, PJ; Pineda, A; Sánchez Rosenberg, GF, 2018)
" Intravenous administration of prednisolone was initiated on suspicion of lacrimal gland inflammation (pseudotumor)."	3.76	Case of lacrimal gland inflammation associated with ulcerative colitis. ( Katsumura, N; Mochizuki, K; Sawada, A, 2010)
" Given the circumstantial evidence of a beneficial effect of prednisolone on pain and paresis, this report evaluates the effects of prednisolone treatment administered in the acute phase in a retrospective case series of 50 NA patients."	3.75	Evaluation of prednisolone treatment in the acute phase of neuralgic amyotrophy: an observational study. ( Berrevoets, M; Pillen, S; van Alfen, N; van der Wilt, GJ; van Eijk, JJ; van Engelen, BG, 2009)
" The presenting symptoms were reduced vision and pain around the left eye."	3.67	Juxtapapillary chorioretinitis in neurosyphilis. A case report. ( Eide, N; Skjeldal, O, 1984)
"50 consecutive patients of untreated lateral epicondylitis were enrolled."	2.78	Comparison of short term results of single injection of autologous blood and steroid injection in tennis elbow: a prospective study. ( Bachhal, V; Banshiwal, RC; Gaury, Y; Jindal, N; Lamoria, R, 2013)
"We conclude that transplantation of autologous BMC via LP is a feasible and safe technique, but at the moment, no clear answer can be given regarding the clinical potential, despite a potential tendency to treat SCI patients, observed through statistics."	2.77	Clinical safety and primary efficacy of bone marrow mesenchymal cell transplantation in subacute spinal cord injured patients. ( Eskandary, H; Karamouzian, S; Nakhaee, N; Nematollahi-Mahani, SN, 2012)
"Adhesive capsulitis or frozen shoulder is a common condition characterized by shoulder pain and stiffness in which conservative methods of treatment such as glucocorticosteroids, anti-inflammatory drugs, and physiotherapy play a significant part."	2.73	Pain relieving effect of short-course, pulse prednisolone in managing frozen shoulder. ( Haghighi, MH; Hemmati, AA; Saeidian, SR, 2007)
"Pamidronate treatment also did not have any influence on patient survival or on the frequency of hypercalcaemia."	2.69	Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group. ( Abildgaard, N; Brincker, H; Ford, J; Gimsing, P; Hedenus, M; Kandra, A; Turesson, I; Westin, J, 1998)
"Orthoptic examination revealed 6th nerve palsy."	2.44	Idiopathic orbital inflammation with extensive intra- and extracranial extension presenting as 6th nerve palsy--a case report and literature review. ( Chaudhary, N; Gibson, A; Olver, J; Tay, E, 2008)
"We assessed Demographic data, the Systemic Lupus Erythematosus Activity Index, the Systemic Lupus International Collaborating Clinics Damage Index, Numeric Rating Scale, Fatigue Severity Scale, Body Image Scale, and the ENRICHD Social Support Instrument."	1.72	Prevalence and biopsychosocial factors associated with depressive symptoms among patients living with systemic lupus erythematosus in clinical settings in urban Thailand. ( Narupan, N; Pumpuang, W; Seeherunwong, A, 2022)
"Prednisolone was administered postoperatively."	1.43	IgG4-related disease presenting with destructive sinonasal lesion mimicking malignancy. ( Chen, BN, 2016)
"SD tooth pain was triggered in many vital teeth by cold and/or hot water (84."	1.43	Dentin hypersensitivity-like tooth pain seen in patients receiving steroid therapy: An exploratory study. ( Aida, J; Endo, Y; Harigae, H; Iikubo, M; Ishii, T; Sakamoto, M; Sasano, T; Shoji, N, 2016)
"She had a history of pemphigus vulgaris maintained in remission with azathioprine, with no evidence of active oral or cutaneous disease at the time of presentation."	1.42	A patient with odynophagia and unusual endoscopic findings. ( Chatu, S; Chung-Faye, G; Griffin, J; Potts, J, 2015)
"pain was -19."	1.42	Interplay between patient global assessment, pain, and fatigue and influence of other clinical disease activity measures in patients with active rheumatoid arthritis. ( Egsmose, EL; Madsen, OR, 2015)
"The association of focal myositis with haemodialysis has been reported once previously, but we report the third case in our experience and argue that it is probably more common than previously appreciated."	1.40	Acute exacerbation of previously undiagnosed chronic focal myositis in an Aboriginal patient on maintenance haemodialysis. ( Majoni, SW; Stewart, BJ, 2014)
"Propranolol is a non-selective β adrenergic receptor blocker which antagonises the anti-inflammatory effect of non-steroidal anti-inflammatory drugs via the β1 and β2 adrenergic receptors."	1.37	Effects of epinephrine and cortisol on the analgesic activity of metyrosine in rats. ( Akcay, F; Albayrak, Y; Karatay, S; Polat, B; Saglam, MB; Suleyman, H; Uslu, T; Yildirim, K, 2011)
"Diagnosis of Tachon syndrome is made by elimination of the usual medical and surgical causes, and physicians performing local injections should be aware of this phenomenon."	1.34	An unusual complication of intra-articular injections of corticosteroids: Tachon syndrome. Two case reports. ( Hajjioui, A; Nys, A; Poiraudeau, S; Revel, M, 2007)
"Pain was gradually intensified during her outpatient clinic and she was admitted."	1.33	[A case of fibromyalgia treated with medical and autogenic training]. ( Asama, Y; Goto, F; Nakai, K, 2005)
"Sweet's syndrome is an uncommon acute skin disease, associated with a variety of medical problems."	1.33	Bortezomib-induced Sweet's syndrome. ( De Raeve, H; Lambert, J; Rombouts, S; Schroyens, W; Van de Velde, A; Van de Voorde, K; Van Regenmortel, N, 2005)
"Hypogonadism has been established as a cause of osteoporosis in males, and in this case would explain the occurrence of fractures in the absence of other major risk factors."	1.31	Osteoporosis with underlying connective tissue disease: an unusual case. ( De Silva, M; Prasad, R, 2002)
"In type I Gaucher's disease, episodes of severe disabling bone pain, the so called bone crises, may be resistant to all analgesics, including narcotics."	1.29	Effective treatment of painful bone crises in type I gaucher's disease with high dose prednisolone. ( Cohen, IJ; Katz, K; Kornreich, L; Mekhmandarov, S; Zaizov, R, 1996)
"Prednisolone was dramatically effective in alleviating the myalgia as well as the other signs of panniculitis."	1.28	Myalgia as the major symptom in systemic panniculitis (Weber-Christian disease). ( Koh, CS; Ohara, S; Yanagisawa, N, 1992)
"Eosinophilic fasciitis (EF) was diagnosed in a 23-year-old man presenting characteristic symptoms, skin changes, blood eosinophilia and typical histology showing thickened deep dermal fascia with inflammatory cells."	1.28	Compartment syndrome as a late complication of eosinophilic fasciitis. ( Fräki, J; Niskanen, L; Tahvanainen, K; Tulla, H, 1989)
"A patient with ulcerative colitis presenting with vasculitic purpura is reported."	1.27	A case of ulcerative colitis presenting as vasculitic purpura. ( McCarthy, CF; McDermott, V, 1985)
"Estramustine has been shown previously to be an effective drug in the treatment of metastatic prostatic cancer, demonstrating significant objective and subjective responses in long-term non-randomized trials and in other randomized trials."	1.26	The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiation. ( Chu, TM; Gaeta, JF; Gibbons, RP; Johnson, DE; Loening, SA; Murphy, GP; Prout, GR; Saroff, J; Schmidt, JD; Scott, WW; Slack, N; Soloway, MS; Wajsman, Z, 1979)

Research

Studies (160)

Authors

Clinical Trials (9)

Trial Overview

Trial Outcomes

Part A: Number of Patients With Dose Limiting Toxicities (DLTs)

Timeframe	Studies, this research(%)	All Research%
pre-1990	61 (38.13)	18.7374
1990's	16 (10.00)	18.2507
2000's	32 (20.00)	29.6817
2010's	37 (23.13)	24.3611
2020's	14 (8.75)	2.80

Authors	Studies
Narupan, N	1
Seeherunwong, A	1
Pumpuang, W	1
van der Meulen, C	1
van de Stadt, LA	2
Kroon, FPB	2
Kortekaas, MC	1
Boonen, AERCH	1
Böhringer, S	1
Niesters, M	1
Reijnierse, M	1
Rosendaal, FR	1
Riyazi, N	1
Starmans-Kool, M	1
Turkstra, F	1
van Zeben, J	1
Allaart, CF	1
Kloppenburg, M	2
Thudium, CF	1
Bay-Jensen, AC	1
Saad, F	1
Thiery-Vuillemin, A	1
Wiechno, P	1
Alekseev, B	1
Sala, N	1
Jones, R	1
Kocak, I	1
Chiuri, VE	1
Jassem, J	1
Fléchon, A	1
Redfern, C	1
Kang, J	1
Burgents, J	1
Gresty, C	1
Degboe, A	1
Clarke, NW	1
Griffiths-Jones, DJ	1
Garcia, YS	1
Ryder, WD	1
Pauling, JD	1
Hall, F	1
Lanyon, P	1
Bhat, S	1
Douglas, K	1
Gunawardena, H	1
Akil, M	1
Anderson, M	1
Griffiths, B	1
Del Galdo, F	1
Youssef, H	1
Madhok, R	1
Arthurs, B	1
Buch, M	1
Fligelstone, K	1
Zubair, M	1
Mason, JC	1
Denton, CP	1
Herrick, AL	1
Hegde, V	1
Shanmugasundaram, S	1
Shaikh, S	1
Kulkarni, V	1
Suresh, N	1
Setzer, FC	1
Nagendrababu, V	1
Witt, AM	1
Kodal, LS	1
Pedersen, BS	1
Lund, EL	1
Dysgaard, T	1
Pisaniello, HL	1
Lester, S	1
Russell, O	1
Black, R	1
Tieu, J	1
Richards, B	1
Barrett, C	1
Lassere, M	1
March, L	1
Buchbinder, R	1
Whittle, SL	1
Hill, CL	1
Nattis, AS	1
Rosenberg, ED	1
Rasool, F	1
Truthmann, J	1
Freyer Martins Pereira, J	1
Richter, A	1
Schuster, F	1
Witte, A	1
Böhm, S	1
Greser, A	1
Kamin, P	1
Stracke, S	1
Dörr, M	1
Bülow, R	1
Engeli, S	1
Gágyor, I	1
Hummers, E	1
Chenot, JF	1
Zeng, J	1
Jia, A	1
Zhang, J	1
Gao, B	1
Xu, J	1
Xing, Y	1
Jing, X	1
Jiao, Y	1
Wang, J	1
Xu, W	1
Gao, L	1
Shang, L	1
Xu, S	1
Tsunoda, K	1
Endo, R	1
El Hasbani, G	1
Taher, AT	1
Jawad, ASM	1
Uthman, I	1
Palacios Argueta, PJ	1
Sánchez Rosenberg, GF	1
Pineda, A	1
McFarlane, M	1
Azam, A	1
Snead, D	1
Disney, B	1
Stevens, SL	1
Schweitzer, D	1
Efe, C	1
Ozaslan, E	1
Purnak, T	1
Zhao, FC	1
Guo, KJ	1
Li, ZR	1
Cheung, FY	1
Leung, KC	1
Ngan, RK	1
Jindal, N	1
Gaury, Y	1
Banshiwal, RC	1
Lamoria, R	1
Bachhal, V	1
Lisitsyna, TA	1
Vel'tishchev, DIu	1
Gerasimov, AN	1
Seravina, OF	1
Kovalevskaia, OB	1
Zel'tyn', AE	1
Novikov, AA	1
Aleksandrova, EN	1
Tallerova, AV	1
Kovalenko, LP	1
Birgens, H	1
Frederiksen, H	1
Hasselbalch, HC	1
Rasmussen, IH	1
Nielsen, OJ	1
Kjeldsen, L	1
Larsen, H	1
Mourits-Andersen, T	1
Plesner, T	1
Rønnov-Jessen, D	1
Vestergaard, H	1
Klausen, TW	1
Schöllkopf, C	1
Cooper, AJ	1
Powell, FC	1
Tsuchida, M	1
Fukushima, T	1
Makino, K	1
Miida, H	1
Kuwabara, T	1
Hafner, F	1
Hackl, G	1
Haas, E	1
Eller, P	1
Gstettner, C	1
Vollmann, R	1
Brodmann, M	1
Stewart, BJ	1
Majoni, SW	1
Houssaini, GS	1
Tahiri, L	1
Ibrahimi, A	1
Tizniti, S	1
Elmrini, A	1
Harzy, T	1
Kajimoto, M	1
Koga, M	1
Narumi, H	1
Inoue, H	1
Matsushige, T	1
Ohga, S	1
Egsmose, EL	1
Madsen, OR	1
Inkpen, H	1
Antunes, H	1
Patraquim, C	1
Baptista, V	1
Silva Monteiro, L	1
Griffin, J	1
Potts, J	1
Chatu, S	1
Chung-Faye, G	1
Rainer, TH	1
Cheng, CH	1
Janssens, HJ	1
Man, CY	1
Tam, LS	1
Choi, YF	1
Yau, WH	1
Lee, KH	1
Graham, CA	1
Takaki, M	1
Inozume, T	1
Sano, S	1
Mitsui, H	1
Kawamura, T	1
Shimada, S	1
Chen, BN	1
Denman, M	1
Shoji, N	1
Endo, Y	1
Iikubo, M	1
Ishii, T	1
Harigae, H	1
Aida, J	1
Sakamoto, M	1
Sasano, T	1
Ribeiro, MI	1
Cardoso, N	1
Pires, S	1
Veloso, T	1
Barata, C	1
Lu, CS	1
Liu, JH	1
Lange, JM	1
Lundberg, GD	1
MacIver, H	1
Hordon, L	1
Tay, E	1
Gibson, A	1
Chaudhary, N	1
Olver, J	1
Mochizuki, K	1
Sawada, A	1
Katsumura, N	1
van Eijk, JJ	1
van Alfen, N	1
Berrevoets, M	1
van der Wilt, GJ	1
Pillen, S	1
van Engelen, BG	1
Nakajima, M	1
Ueda, N	1
Ohara, H	1
Abe, M	1
Kinoshita, M	1
Berg, T	1
Axelsson, S	1
Engström, M	1
Stjernquist-Desatnik, A	1
Pitkäranta, A	1
Kanerva, M	1
Jonsson, L	1
Valleala, H	1
Korpela, M	1
Möttönen, T	1
Hienonen-Kempas, T	1
Kauppi, M	1
Hannonen, P	1
Leirisalo-Repo, M	1
Ohnuma, K	1
Hosono, O	1
Katayose, T	1
Yoshikawa, N	1
Kawasaki, H	1
Fujii, T	1
Oyaizu, N	1
Tanaka, H	1
Morimoto, C	1
Femiano, F	1
Buonaiuto, C	1
Gombos, F	1
Lanza, A	1
Cirillo, N	1
Elmantaser, M	1
Stewart, G	1
Young, D	1
Duncan, R	1
Gibson, B	1
Ahmed, SF	1
Gan, NY	1
King, LL	1
Teoh, SC	1
Nagai, Y	1
Igarashi, N	1
Ishikawa, O	1
Böttcher, A	1
Guder, E	1
Just, T	1
Mehta, P	1
Patel, L	1
Roncaroli, F	1
Pickering, MC	1
Brand, A	1
Albayrak, Y	1
Saglam, MB	1
Yildirim, K	1
Karatay, S	1
Polat, B	1
Uslu, T	1
Suleyman, H	1
Akcay, F	1
Karamouzian, S	1
Nematollahi-Mahani, SN	1
Nakhaee, N	1
Eskandary, H	1
Divala, T	1
Rylance, J	1
Prasad, R	1
De Silva, M	1
Rodriguez, N	1
Eliott, D	1
Garcia-Valenzuela, E	1
Baker, J	1
Ostör, AJ	1
Hazleman, BL	2
Horiguchi, A	1
Uchida, A	1
KOS, R	1
VOTIN, J	1
BUTTERWORTH, RF	1
KAESER, HE	1
LOCKE, RK	1
STRAUSS, H	1
BURROWS, FG	1
Watanabe, T	1
Abe, Y	2
Hauswirth, AW	1
Simonitsch-Klupp, I	1
Uffmann, M	1
Koller, E	1
Sperr, WR	1
Lechner, K	1
Valent, P	1
Rousseff, RT	1
Simeonov, S	1
Rexer, H	1
Soylu, A	1
Oztürk, Y	1
Kasap, B	1
Akman, N	1
Türkmen, M	1
Kavukçu, S	1
Monzillo, PH	1
Saab, VM	1
Protti, GG	1
Costa, AR	1
Sanvito, WL	1
Whitehouse, MW	1
Goto, F	1
Asama, Y	1
Nakai, K	1
Van Regenmortel, N	1
Van de Voorde, K	1
De Raeve, H	1
Rombouts, S	1
Van de Velde, A	1
Lambert, J	1
Schroyens, W	1
Cohen, J	1
Iwatani, M	1
Inoue, E	1
Nakamura, T	1
Nakajima, A	2
Hara, M	1
Tomatsu, T	1
Kamatani, N	1
Yamanaka, H	1
Medeiros, D	1
Laufenberg, JA	1
Miller, KL	1
Buchanan, GR	1
Saeidian, SR	1
Hemmati, AA	1
Haghighi, MH	1
Hutchings, A	1
Hollywood, J	1
Lamping, DL	1
Pease, CT	1
Chakravarty, K	1
Silverman, B	1
Choy, EH	1
Scott, DG	1
Bourke, B	1
Gendi, N	1
Dasgupta, B	1
Yanagisawa, S	1
Inamori, M	1
Endo, H	1
Iida, H	1
Akimoto, K	1
Sakamoto, Y	1
Akiyama, T	1
Fujita, K	1
Yoneda, M	1
Takahashi, H	1
Kobayashi, N	1
Kirikoshi, H	1
Kubota, K	1
Ueno, N	1
Song, YW	1
Lee, EY	1
Koh, EM	1
Cha, HS	1
Yoo, B	1
Lee, CK	1
Baek, HJ	1
Kim, HA	1
Suh, Y	1
Kang, SW	1
Lee, YJ	1
Jung, HG	1
Hajjioui, A	1
Nys, A	1
Poiraudeau, S	1
Revel, M	1
Sullivan, FM	1
Swan, IR	1
Donnan, PT	1
Morrison, JM	1
Smith, BH	1
McKinstry, B	1
Davenport, RJ	1
Vale, LD	1
Clarkson, JE	1
Hammersley, V	1
Hayavi, S	1
McAteer, A	1
Stewart, K	1
Daly, F	1
Hope-Simpson, RE	1
Law, MR	1
Hodson, ME	1
Turner-Warwick, M	1
Graf, D	1
Engelhardt, D	1
Permanetter, W	1
Eide, N	1
Skjeldal, O	1
Mehta, BC	1
Temin, PA	1
Gerasimova, OI	1
Mulley, GP	1
Shiga, H	1
Toda, T	1
Ono, T	1
Mochizuki, H	1
Matsunaga, J	1
Asano, S	1
Cohen, IJ	1
Kornreich, L	1
Mekhmandarov, S	1
Katz, K	1
Zaizov, R	1
Ganesan, V	1
Lin, JP	1
Chong, WK	1
Kirkham, FJ	1
Surtees, RA	1
Gøtzsche, PC	1
Johansen, HK	1
Brincker, H	1
Westin, J	1
Abildgaard, N	1
Gimsing, P	1
Turesson, I	1
Hedenus, M	1
Ford, J	1
Kandra, A	1
Burnstein, Y	1
Shelton, K	1
Higginbotham, EJ	1
Hickling, P	1
Jacoby, RK	1
Kirwan, JR	1
Elstein, D	1
Abrahamov, A	1
Itzchaki, M	1
Zimran, A	1
Yoon, KH	1
Ng, SC	1
Distelrath, K	1
Neuber, K	1
Blödorn-Schlicht, N	1
Altenhoff, J	1
Dührsen, U	1
Düring, J	1
Steinkraus, V	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase II Study to Compare the Efficacy, Safety and Tolerability of Olaparib Versus Placebo When Given in Addition to Abiraterone Treatment in Patients With Metastatic Castrate-Resistant Prostate [NCT01972217]	Phase 2	158 participants (Actual)	Interventional	2014-04-01	Completed
Eccentric Exercise in Epicondylitis: Direct Application By Physical Therapist Vs Self-Application By Patient[NCT03996928]		20 participants (Anticipated)	Interventional	2017-01-01	Recruiting
Treatment of Intractable Common Extensor Tendon Injury Using Allogeneic Adipose-derived Mesenchymal Stem Cells (Allo-ASC): a Phase II Randomized Controlled Trial[NCT03449082]	Phase 2	30 participants (Actual)	Interventional	2018-05-04	Active, not recruiting
Sirolimus in the Treatment of Refractory/Relapsed Warm Autoimmune Hemolytic Anemia (AIHA)： a Phase 2 Prospective Trial[NCT05925023]	Phase 2	22 participants (Anticipated)	Interventional	2023-06-24	Recruiting
Zanubrutinib in Relapsed or Refractory Warm Autoimmune Hemolytic Anemia: a Prospective Cohort Study[NCT05922839]	Phase 2	22 participants (Anticipated)	Interventional	2023-06-30	Not yet recruiting
The Safety of Repurposing Daratumumab for Relapsed or Refractory Autoimmune Antibody Mediated Hemolytic Anemia[NCT05004259]	Phase 1	10 participants (Anticipated)	Interventional	2022-03-21	Recruiting
Autologous Transplantation of Bone Marrow Mesenchymal Stem Cells in Patients of Spinal Cord Injury-Phase I Clinical Trial[NCT02482194]	Phase 1	9 participants (Actual)	Interventional	2013-06-30	Completed
Is There Any Advantage of PRP Over Autologous Blood Injection in the Treatment of Chronic Plantar Fasciitis? A Prospective Randomized Double Blinded Study[NCT05240872]	Phase 3	60 participants (Actual)	Interventional	2020-03-01	Completed
A Study Into the Use of Prefabricated Orthotics in Shoes, in Combination With Using Indoor Comfort Sandals With built-in Arch Support vs. the Sole Use of Prefabricated Orthotics in Shoes Alone, for the Treatment of Plantar Fasciitis. A Randomised Control [NCT04894383]		104 participants (Actual)	Interventional	2021-07-23	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"DLTs were assessed by a Safety Review Committee (SRC) after a minimum of 3 patients had received at least 14 days of treatment in Part A.~A DLT was defined as any toxicity which was not a recognised AE of abiraterone or prednisolone, and was not attributable to the disease or disease-related processes under investigation, which occurred during a minimum period of 14 days treatment and which included: 1. haematological toxicity CTCAE v4.0 Grade 4 or higher present for more than 4 days (except anaemia); 2. non-haematological toxicity CTCAE v4.0 Grade 3 or higher including infection, corrected QT interval prolongation; 3. any other toxicity that was greater than that at baseline, was clinically significant and/or unacceptable, did not respond to supportive care, resulted in a disruption of dosing schedule of 7 days or more, or was judged to be a DLT by the SRC.~A DLT excluded alopecia and isolated laboratory changes of any grade without clinical sequelae or clinical significance." (NCT01972217)
Timeframe: From Day 1 for Cohort 1 and from Day 4 for Cohort 2 up to 14 days treatment with olaparib + abiraterone for 3 patients.

Part B: Median Best Percentage Change From Baseline in Circulating Tumour Cell (CTC) Level

Intervention	Patients (Number)
Part A Cohort 1: Olaparib 200 mg + Abiraterone	2
Part A Cohort 2: Olaparib 300 mg + Abiraterone	4

"The median best percentage change from baseline in CTC levels was determined to assess the anti-tumour activity of olaparib when given in combination with abiraterone, compared with placebo given in addition to abiraterone.~The best percentage change was defined as the biggest CTC level reduction compared with baseline or smallest increase in the absence of a decrease." (NCT01972217)
Timeframe: From baseline, then every 4 weeks up to Week 24, and then every 12 weeks.

Part B: Median Best Percentage Change From Baseline in Prostate Specific Antigen (PSA) Levels

Intervention	Percentage change in CTC level (Median)
Part B: Olaparib + Abiraterone	-1.0
Part B: Placebo + Abiraterone	-1.0

"The best percentage change from baseline in PSA levels was determined to assess the anti-tumour activity of olaparib when given in addition to abiraterone, compared with placebo given in addition to abiraterone.~The best percentage change was defined as the biggest reduction in PSA level compared with baseline or smallest increase in the absence of a decrease." (NCT01972217)
Timeframe: From baseline, then every 4 weeks up to Week 52, and then every 12 weeks.

Part B: Median Overall Survival (OS)

Intervention	Percentage change in PSA level (Median)
Part B: Olaparib + Abiraterone	-54.16
Part B: Placebo + Abiraterone	-49.85

"OS was determined to assess the efficacy of olaparib when given in addition to abiraterone, compared with placebo given in addition to abiraterone.~OS was performed at the time of the analysis of rPFS, and the median OS, calculated using the Kaplan-Meier technique, is presented." (NCT01972217)
Timeframe: From baseline, every 12 weeks up to Week 72, then every 24 weeks up to 24 months.

Part B: Median Radiological Progression-Free Survival (rPFS) Time

Intervention	Months (Median)
Part B: Olaparib + Abiraterone	22.7
Part B: Placebo + Abiraterone	20.9

"The efficacy of olaparib when given in combination with abiraterone was assessed by rPFS, defined as the time from randomisation to disease progression using Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (for soft tissue disease) and Prostate Cancer Working Group 2 (PCWG-2) (for bone disease) criteria, or death.~Progression using RECIST 1.1 criteria was defined as at least 20% increase from baseline in the sum of diameters of target lesions, progression of existing non-target lesions, or the appearance of at least 1 new lesion.~Progression using PCWG-2 criteria was determined if 2 or more new metastatic bone lesions were observed (with a total of at least 4 new lesions since baseline assessment if observed at the 12 week scan, or persistence of or increase in number of lesions if observed after the 12 week scan as determined by a confirmatory scan at least 6 weeks later or at next scheduled visit)." (NCT01972217)
Timeframe: From baseline, every 12 weeks up to Week 72, then every 24 weeks up to 24 months.

Part B: Median Time to Second Progression or Death (PFS2)

Intervention	Months (Median)
Part B: Olaparib + Abiraterone	13.8
Part B: Placebo + Abiraterone	8.2

The efficacy of olaparib when given in combination with abiraterone was assessed by PFS2, defined by local standard clinical practice and included objective radiological progression by RECIST 1.1 (soft tissue), symptomatic progression, rise in PSA level or death in the absence of overall progression. (NCT01972217)
Timeframe: From randomisation until analysis cut-off date (up to approximately 3 years).

Part B: Percentage of Patients With at Least One Objective Response (Objective Response Rate [ORR])

Intervention	Months (Median)
Part B: Olaparib + Abiraterone	23.3
Part B: Placebo + Abiraterone	18.5

"The overall radiological ORR was calculated to assess the anti-tumour activity of olaparib in combination with abiraterone, compared with placebo in combination with abiraterone.~The best overall ORR was defined as the percentage of patients with at least 1 visit response of complete response (CR) or partial response (PR) in soft tissue disease assessed by RECIST 1.1 and also bone scan status of non-progressive disease or non-evaluable for their bone scans assessed by PCWG-2.~CR: Disappearance of all target lesions. Reduction of pathological lymph nodes to <10 millimetres.~PR: At least a 30% decrease in the sum of diameters of target lesions from baseline.~The percentage of patients with a response is presented." (NCT01972217)
Timeframe: From baseline, then every 4 weeks up to Week 52, and then every 12 weeks.

Part B: Percentage of Patients With Progression Events or Death (rPFS)

Intervention	Percentage of patients (Number)
Part B: Olaparib + Abiraterone	27.3
Part B: Placebo + Abiraterone	31.6

"The efficacy of olaparib when given in combination with abiraterone was assessed by rPFS, defined as the time from randomisation to disease progression using RECIST version 1.1 (for soft tissue disease) and PCWG-2 (for bone disease) criteria, or death.~Progression using RECIST 1.1 criteria was defined as at least 20% increase from baseline in the sum of diameters of target lesions, progression of existing non-target lesions, or the appearance of at least 1 new lesion.~Progression using PCWG-2 criteria was determined if 2 or more new metastatic bone lesions were observed (with a total of at least 4 new lesions since baseline assessment if observed at the 12 week scan, or persistence of or increase in number of lesions if observed after the 12 week scan as determined by a confirmatory scan at least 6 weeks later or at next scheduled visit).~The percentage of patients with progression events is presented overall and according to RECIST 1.1 and/or PCWG-2 criteria, or death." (NCT01972217)
Timeframe: From baseline, every 12 weeks up to Week 72, then every 24 weeks up to 24 months.

Median Time to First Subsequent Therapy (TFST) and Median Time to Second Subsequent Therapy (TSST)

Intervention	Percentage of patients (Number)
Part B: Olaparib + Abiraterone	64.8
Part B: Placebo + Abiraterone	76.1

"The TFST and TSST were determined to assess the anti-tumour activity of olaparib when given in combination with abiraterone, compared with placebo given in addition to abiraterone.~TFST was defined as the time from randomisation to the earlier of first subsequent anti-cancer therapy start date following study treatment discontinuation, or death.~TSST was defined as the time from randomisation to the earlier of the second subsequent anti-cancer therapy start date following study treatment discontinuation, or death." (NCT01972217)
Timeframe: From randomisation until analysis cut-off date (up to approximately 3 years).

Part A Pharmacokinetics (PK): Olaparib Maximum Plasma Concentration at Steady State (Cmax,ss)

Intervention	Months (Median)
	TFST	TSST
Part B: Olaparib + Abiraterone	13.5	19.6
Part B: Placebo + Abiraterone	9.7	18.0

"Following multiple dosing to steady state of olaparib 300 mg bid, the Cohort 2 olaparib Cmax,ss is presented for olaparib monotherapy and for olaparib given in combination with abiraterone.~Only patients with data available for analysis at each time point are presented." (NCT01972217)
Timeframe: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.

Part A Pharmacokinetics (PK): Olaparib Maximum Plasma Concentration at Steady State (Cmax,ss)

Intervention	micrograms per millilitre (mcg/mL) (Geometric Mean)
	Olaparib + abiraterone
Part A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone	7.724

Part A PK Analysis: Olaparib Area Under the Plasma Concentration-Time Curve at Steady State (AUCss)

Intervention	micrograms per millilitre (mcg/mL) (Geometric Mean)
	Olaparib alone	Olaparib + abiraterone
Part A Cohort 2 Group 1: Olaparib, Olaparib + Abiraterone	7.781	6.504

"Following multiple dosing to steady state of olaparib 300 mg bid, the Cohort 2 olaparib AUCss is presented for olaparib monotherapy and for olaparib given in combination with abiraterone.~Only patients with data available for analysis at each time point are presented." (NCT01972217)
Timeframe: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.

Part A PK Analysis: Olaparib Area Under the Plasma Concentration-Time Curve at Steady State (AUCss)

Intervention	mcg*h/mL (Geometric Mean)
	Olaparib + abiraterone
Part A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone	49.51

Part A PK Analysis: Olaparib Minimum Plasma Concentration at Steady State (Cmin,ss)

Intervention	mcg*h/mL (Geometric Mean)
	Olaparib alone	Olaparib + abiraterone
Part A Cohort 2 Group 1: Olaparib, Olaparib + Abiraterone	45.27	40.83

"Following multiple dosing to steady state of olaparib 300 mg bid, the Cohort 2 olaparib Cmin,ss is presented for olaparib monotherapy and for olaparib given in combination with abiraterone.~Only patients with data available for analysis at each time point are presented." (NCT01972217)
Timeframe: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.

Part A PK Analysis: Olaparib Minimum Plasma Concentration at Steady State (Cmin,ss)

Intervention	mcg/mL (Geometric Mean)
	Olaparib + abiraterone
Part A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone	1.279

Part A PK Analysis: Olaparib Time to Reach Maximum Plasma Concentration at Steady State (Tmax,ss)

Intervention	mcg/mL (Geometric Mean)
	Olaparib alone	Olaparib + abiraterone
Part A Cohort 2 Group 1: Olaparib, Olaparib + Abiraterone	1.264	0.9170

"Following multiple dosing to steady state of olaparib 300 mg bid, the Cohort 2 olaparib tmax,ss is presented for olaparib monotherapy and for olaparib given in combination with abiraterone.~Only patients with data available for analysis at each time point are presented." (NCT01972217)
Timeframe: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.

Part A PK Analysis: Olaparib Time to Reach Maximum Plasma Concentration at Steady State (Tmax,ss)

Intervention	Hours (h) (Median)
	Olaparib + abiraterone
Part A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone	2.000

Part A PK: Abiraterone AUCss

Intervention	Hours (h) (Median)
	Olaparib alone	Olaparib + abiraterone
Part A Cohort 2 Group 1: Olaparib, Olaparib + Abiraterone	2.000	2.080

"Following multiple dosing to steady state of abiraterone 1000 mg once daily, the Cohort 2 abiraterone AUCss is presented for abiraterone monotherapy and for olaparib given in combination with abiraterone.~Only patients with data available for analysis at each time point are presented." (NCT01972217)
Timeframe: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.

Part A PK: Abiraterone AUCss

Intervention	ng*h/mL (Geometric Mean)
	Olaparib + abiraterone
Part A Cohort 2 Group 1: Olaparib, Olaparib + Abiraterone	718.9

Part A PK: Abiraterone Cmax,ss

Intervention	ng*h/mL (Geometric Mean)
	Abiraterone alone	Olaparib + abiraterone
Part A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone	825.5	524.6

"Following multiple dosing to steady state of abiraterone 1000 mg once daily, the Cohort 2 abiraterone Cmax,ss is presented for abiraterone monotherapy and for olaparib given in combination with abiraterone.~Only patients with data available for analysis at each time point are presented." (NCT01972217)
Timeframe: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.

Part A PK: Abiraterone Cmax,ss

Intervention	nanograms per millilitre (ng/mL) (Geometric Mean)
	Olaparib + abiraterone
Part A Cohort 2 Group 1: Olaparib, Olaparib + Abiraterone	130.7

Part A PK: Abiraterone Cmin,ss

Intervention	nanograms per millilitre (ng/mL) (Geometric Mean)
	Abiraterone alone	Olaparib + abiraterone
Part A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone	145.8	86.12

"Following multiple dosing to steady state of abiraterone 1000 mg once daily, the Cohort 2 abiraterone Cmin,ss is presented for abiraterone monotherapy and for olaparib given in combination with abiraterone.~Only patients with data available for analysis at each time point are presented." (NCT01972217)
Timeframe: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.

Part A PK: Abiraterone Cmin,ss

Intervention	ng/mL (Geometric Mean)
	Olaparib + abiraterone
Part A Cohort 2 Group 1: Olaparib, Olaparib + Abiraterone	7.983

Part A PK: Abiraterone Tmax,ss

Intervention	ng/mL (Geometric Mean)
	Abiraterone alone	Olaparib + abiraterone
Part A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone	8.376	6.358

"Following multiple dosing to steady state of abiraterone 1000 mg once daily, the Cohort 2 abiraterone tmax,ss is presented for abiraterone monotherapy and for olaparib given in combination with abiraterone.~Only patients with data available for analysis at each time point are presented." (NCT01972217)
Timeframe: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.

Part A PK: Abiraterone Tmax,ss

Intervention	Hours (Median)
	Olaparib + abiraterone
Part A Cohort 2 Group 1: Olaparib, Olaparib + Abiraterone	3.000

Part A: Percentage of Patients Experiencing Adverse Events (AEs)

Intervention	Hours (Median)
	Abiraterone alone	Olaparib + abiraterone
Part A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone	2.525	2.500

"The safety and tolerability of olaparib in combination with abiraterone was assessed during Part A of the study. The percentage of patients experiencing AEs, including information on seriousness, severity, study treatment relationship and those leading to discontinuation for all doses of olaparib and for abiraterone are presented.~Severity of AEs was assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse events (CTCAE) v4.0. AEs were assigned to a Grade from 1 through 5 as follows:~Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life-threatening requiring hospitalisation; Grade 4: Life-threatening consequences; Grade 5: Death related to AE.~'c-r' = causally related 'discont' = discontinuation." (NCT01972217)
Timeframe: Cohort 1 and 2: From baseline in Part A (Day 1 for each cohort) up to 30 days following last dose of study treatment.

Part B: Percentage of Patients Experiencing AEs

Intervention	Percentage of patients (Number)
	Any AE c-r to olaparib + abiraterone	Any AE c-r to olaparib only	Any AE c-r to abiraterone only	Any AE CTCAE Grade 3 or higher	Any AE CTCAE Grade 3 or higher c-r to olaparib	Any AE CTCAE Grade 3 or higher c-r to abiraterone	Any AE with outcome = death	Any serious AE (SAE)	Any SAE c-r to olaparib	Any SAE c-r to abiraterone	Any AE causing discont of olaparib	Any AE causing discont of olaparib c-r to olaparib	Any AE causing discont olaparib c-r to abiraterone
Part A Cohort 1: Olaparib 200 mg + Abiraterone	66.7	33.3	0	66.7	0	0	0	66.7	0	0	0	0	0
Part A Cohort 2: Olaparib 300 mg + Abiraterone	46.2	7.7	15.4	23.1	7.7	7.7	0	23.1	0	0	7.7	0	0

"The safety and tolerability of olaparib when given in combination with abiraterone was assessed during Part B of the study. The percentage of patients experiencing AEs, including information on seriousness, severity, study treatment relationship and those leading to discontinuation for all doses of olaparib and for abiraterone are presented.~Severity of AEs was assessed using the NCI Common Terminology CTCAE v4.0. AEs were assigned to a Grade from 1 through 5 as follows:~Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life-threatening requiring hospitalisation; Grade 4: Life-threatening consequences; Grade 5: Death related to AE.~'c-r' = causally related. 'discont' = discontinuation. 'ola/pla' = olaparib/placebo." (NCT01972217)
Timeframe: From first dose of study treatment following randomisation in Part B up to 30 days following last dose of study treatment (up to approximately 3 years).

Part B: Percentage of Patients With PSA Responses

Intervention	Percentage of patients (Number)
	Any AE c-r to ola/pla + abiraterone	Any AE c-r to ola/pla only	Any AE c-r to abiraterone only	Any AE CTCAE Grade 3 or higher	Any AE CTCAE Grade 3 or higher c-r to ola/pla	Any AE CTCAE Grade 3 or higher c-r to abiraterone	Any AE with outcome = death	Any AE with outcome = death c-r to ola/pla	Any AE with outcome = death c-r to abiraterone	Any SAE	Any SAE c-r to ola/pla	Any SAE c-r to abiraterone	Any AE causing discont of ola/pla	Any AE causing discont of treatment c-r to ola/pla	Any AE causing discont treatment c-r abiraterone
Part B: Olaparib + Abiraterone	45.1	18.3	1.4	53.5	23.9	16.9	5.6	1.4	0	35.2	9.9	5.6	29.6	16.9	8.5
Part B: Placebo + Abiraterone	12.7	9.9	7.0	28.2	5.6	1.4	1.4	0	0	19.7	1.4	0	9.9	5.6	1.4

"The percentages of patients with single visit responses and with confirmed responses are presented to assess the anti-tumour activity of olaparib when given in addition to abiraterone, compared with placebo given in addition to abiraterone.~A single visit response was defined as any post-dose visit PSA level reduced by 50% or more compared with baseline.~A confirmed response was defined as a reduction in PSA level of 50% or more on 2 consecutive occasions at least 4 weeks apart compared with baseline.~Patients may have had more than 1 single visit response or confirmed response but were counted once." (NCT01972217)
Timeframe: From baseline, then every 4 weeks up to Week 24, and then every 12 weeks.

Intervention	Percentage of patients (Number)
	Single visit response	Confirmed response
Part B: Olaparib + Abiraterone	50.7	47.9
Part B: Placebo + Abiraterone	47.9	42.3

Article	Year
Post-partum eosinophilic gastroenteritis: A case report. Gastroenterologia y hepatologia, 2018, Volume: 41, Issue:1 Topics: Adult; Anti-Inflammatory Agents; Ascites; Biopsy; Endoscopy, Digestive System; Enteritis; Eosinophil	2018
Idiopathic orbital inflammation with extensive intra- and extracranial extension presenting as 6th nerve palsy--a case report and literature review. Orbit (Amsterdam, Netherlands), 2008, Volume: 27, Issue:6 Topics: Abducens Nerve Diseases; Adolescent; Blindness; Diplopia; Drug Therapy, Combination; Headache; Human	2008
Managing the patient with polymyalgia. The Practitioner, 2002, Volume: 246, Issue:1640 Topics: Aged; Anti-Inflammatory Agents; Diagnosis, Differential; Giant Cell Arteritis; Humans; Incidence; Mi	2002
Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leukemia research, 2004, Volume: 28, Issue:3 Topics: Adult; Bone Marrow; Disease Progression; Drug Evaluation; Drug Therapy, Combination; Female; Fever;	2004
[Steroid myopathies (review)]. Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 1980, Volume: 80, Issue:11 Topics: Adolescent; Adrenocortical Hyperfunction; Adult; Aged; Animals; Child; Child, Preschool; Cortisone;	1980
Meta-analysis of short-term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. BMJ (Clinical research ed.), 1998, Mar-14, Volume: 316, Issue:7134 Topics: Administration, Oral; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis,	1998
[Polymyositis associated with HIV immunodeficiency: clinical case and literature review]. Revue medicale de Bruxelles, 2001, Volume: 22, Issue:3 Topics: Adult; Anti-Inflammatory Agents; Biopsy; Deglutition Disorders; Diagnosis, Differential; Female; HIV	2001
Pancreatic cancer. The Surgical clinics of North America, 1975, Volume: 55, Issue:2 Topics: Abdomen; Biopsy; Carcinoma, Intraductal, Noninfiltrating; Celiac Disease; Cholecystokinin; Diabetes	1975
Diagnosis and surgical treatment of carcinoma of the pancreas. Current problems in surgery, 1968 Topics: Adenocarcinoma; Anorexia Nervosa; Body Weight; Constipation; Diabetes Mellitus; Diagnosis, Different	1968
[Glucocorticoid preparations in the therapy of pulpitis]. Den Norske tannlaegeforenings tidende, 1971, Volume: 81, Issue:2 Topics: Animals; Anti-Bacterial Agents; Chloramphenicol; Diagnosis, Differential; Follow-Up Studies; Glucoco	1971
The patient with rheumatoid arthritis. American family physician, 1971, Volume: 4, Issue:1 Topics: Activities of Daily Living; Arthritis, Rheumatoid; Bursitis; Chloroquine; Diagnosis, Differential; F	1971

Article	Year
Neuropathic-like pain symptoms in inflammatory hand osteoarthritis lower quality of life and may not decrease under prednisolone treatment. European journal of pain (London, England), 2022, Volume: 26, Issue:8 Topics: Female; Humans; Male; Middle Aged; Osteoarthritis, Knee; Pain; Pain Measurement; Peripheral Nervous	2022
Serum biomarkers in prednisolone-treated hand osteoarthritis patients. Rheumatology (Oxford, England), 2023, 03-01, Volume: 62, Issue:3 Topics: Biomarkers; C-Reactive Protein; Female; Humans; Male; Middle Aged; Osteoarthritis; Pain; Prednisolon	2023
Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial. The Lancet. Oncology, 2022, Volume: 23, Issue:10 Topics: Androgen Antagonists; Androgens; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Doceta	2022
A Phase II randomized controlled trial of oral prednisolone in early diffuse cutaneous systemic sclerosis (PRedSS). Rheumatology (Oxford, England), 2023, 09-01, Volume: 62, Issue:9 Topics: COVID-19; Double-Blind Method; Humans; Pain; Pandemics; Prednisolone; Scleroderma, Diffuse; Treatmen	2023
Effect of Preoperative Oral Steroids in Comparison to Anti-inflammatory on Anesthetic Success of Inferior Alveolar Nerve Block in Mandibular Molars with Symptomatic Irreversible Pulpitis-A Double-blinded Randomized Clinical Trial. Journal of endodontics, 2023, Volume: 49, Issue:4 Topics: Anesthesia, Dental; Anesthetics, Local; Anti-Inflammatory Agents; Dexamethasone; Double-Blind Method	2023
Intracanalicular dexamethasone insert for post-corneal crosslinking inflammation and pain: the LINK study. Journal of cataract and refractive surgery, 2023, 11-01, Volume: 49, Issue:11 Topics: Cross-Linking Reagents; Dexamethasone; Epithelium, Corneal; Humans; Inflammation; Keratoconus; Ophth	2023
Prednisolone Versus Colchicine for Acute Gout in Primary Care (COPAGO): protocol for a two-arm multicentre, pragmatic, prospective, randomized, double-blind, controlled clinical trial of prednisolone and colchicine for non-inferiority with a parallel grou Trials, 2023, Oct-05, Volume: 24, Issue:1 Topics: Adult; Arthritis, Gouty; Colchicine; Double-Blind Method; Gout; Humans; Multicenter Studies as Topic	2023
Comparison of the therapeutic effects of 15 mg and 30 mg initial daily prednisolone doses in patients with subacute thyroiditis: a multicenter, randomized, open-label, parallel-controlled trial. Annals of medicine, 2023, Volume: 55, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Humans; Hypothyroidism; Pain; Prednisolone; Thyroidi	2023
Comparison of short term results of single injection of autologous blood and steroid injection in tennis elbow: a prospective study. Journal of orthopaedic surgery and research, 2013, Apr-27, Volume: 8 Topics: Adult; Blood Transfusion, Autologous; Female; Glucocorticoids; Humans; Injections, Intra-Articular;	2013
Comparison of short term results of single injection of autologous blood and steroid injection in tennis elbow: a prospective study. Journal of orthopaedic surgery and research, 2013, Apr-27, Volume: 8 Topics: Adult; Blood Transfusion, Autologous; Female; Glucocorticoids; Humans; Injections, Intra-Articular;	2013
Comparison of short term results of single injection of autologous blood and steroid injection in tennis elbow: a prospective study. Journal of orthopaedic surgery and research, 2013, Apr-27, Volume: 8 Topics: Adult; Blood Transfusion, Autologous; Female; Glucocorticoids; Humans; Injections, Intra-Articular;	2013
Comparison of short term results of single injection of autologous blood and steroid injection in tennis elbow: a prospective study. Journal of orthopaedic surgery and research, 2013, Apr-27, Volume: 8 Topics: Adult; Blood Transfusion, Autologous; Female; Glucocorticoids; Humans; Injections, Intra-Articular;	2013
A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. British journal of haematology, 2013, Volume: 163, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derive	2013
A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. British journal of haematology, 2013, Volume: 163, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derive	2013
A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. British journal of haematology, 2013, Volume: 163, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derive	2013
A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. British journal of haematology, 2013, Volume: 163, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derive	2013
A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. British journal of haematology, 2013, Volume: 163, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derive	2013
A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. British journal of haematology, 2013, Volume: 163, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derive	2013
A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. British journal of haematology, 2013, Volume: 163, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derive	2013
A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. British journal of haematology, 2013, Volume: 163, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derive	2013
A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. British journal of haematology, 2013, Volume: 163, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derive	2013
Oral Prednisolone in the Treatment of Acute Gout: A Pragmatic, Multicenter, Double-Blind, Randomized Trial. Annals of internal medicine, 2016, Apr-05, Volume: 164, Issue:7 Topics: Administration, Oral; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Doubl	2016
A comparative study of the effects of bucillamine and salazosulfapyridine in the treatment of rheumatoid arthritis. Modern rheumatology, 2009, Volume: 19, Issue:4 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Cysteine; Drug Therapy, Combination	2009
The course of pain in Bell's palsy: treatment with prednisolone and valacyclovir. Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 2009, Volume: 30, Issue:6 Topics: Acyclovir; Adult; Anti-Inflammatory Agents; Antiviral Agents; Bell Palsy; Double-Blind Method; Earac	2009
Pilot study on recurrent aphthous stomatitis (RAS): a randomized placebo-controlled trial for the comparative therapeutic effects of systemic prednisone and systemic montelukast in subjects unresponsive to topical therapy. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2010, Volume: 109, Issue:3 Topics: Acetates; Adolescent; Adult; Cyclopropanes; Double-Blind Method; Female; Glucocorticoids; Humans; Le	2010
Clinical safety and primary efficacy of bone marrow mesenchymal cell transplantation in subacute spinal cord injured patients. Clinical neurology and neurosurgery, 2012, Volume: 114, Issue:7 Topics: Adult; Anti-Inflammatory Agents; Bone Marrow Transplantation; Cell Differentiation; Female; Follow-U	2012
Efficacy profile of bucillamine in rheumatoid arthritis patients in a large observational cohort study, IORRA. Modern rheumatology, 2006, Volume: 16, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cohort Studies; Cysteine; Drug Thera	2006
Short-term oral corticosteroid therapy for acute haemarthrosis in haemophilia patients with high-titre inhibitors. Haemophilia : the official journal of the World Federation of Hemophilia, 2007, Volume: 13, Issue:1 Topics: Adolescent; Adult; Blood Coagulation Factor Inhibitors; Blood Coagulation Factors; Child; Child, Pre	2007
Pain relieving effect of short-course, pulse prednisolone in managing frozen shoulder. Journal of pain & palliative care pharmacotherapy, 2007, Volume: 21, Issue:1 Topics: Adult; Aged; Anti-Inflammatory Agents; Bursitis; Diclofenac; Female; Humans; Male; Middle Aged; Pain	2007
Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. Arthritis and rheumatism, 2007, Jun-15, Volume: 57, Issue:5 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Blood Sedimentation; Female; Health Status; Human	2007
Assessment of comparative pain relief and tolerability of SKI306X compared with celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, double-dummy, phase III, noninferiority clinical trial. Clinical therapeutics, 2007, Volume: 29, Issue:5 Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Clematis; Cyclooxy	2007
Early treatment with prednisolone or acyclovir in Bell's palsy. The New England journal of medicine, 2007, Oct-18, Volume: 357, Issue:16 Topics: Acyclovir; Adult; Antiviral Agents; Bell Palsy; Double-Blind Method; Drug Therapy, Combination; Faci	2007
Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group. British journal of haematology, 1998, Volume: 101, Issue:2 Topics: Administration, Oral; Aged; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols	1998
Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. British journal of rheumatology, 1998, Volume: 37, Issue:9 Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Finger Joi	1998
Steroid injection for heel pain: evidence of short-term effectiveness. A randomized controlled trial. Rheumatology (Oxford, England), 1999, Volume: 38, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Anesthetics, Local; Double-Blind Method; Fasciitis; Female; Foot Dis	1999
Steroid injection for heel pain: evidence of short-term effectiveness. A randomized controlled trial. Rheumatology (Oxford, England), 1999, Volume: 38, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Anesthetics, Local; Double-Blind Method; Fasciitis; Female; Foot Dis	1999
Steroid injection for heel pain: evidence of short-term effectiveness. A randomized controlled trial. Rheumatology (Oxford, England), 1999, Volume: 38, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Anesthetics, Local; Double-Blind Method; Fasciitis; Female; Foot Dis	1999
Steroid injection for heel pain: evidence of short-term effectiveness. A randomized controlled trial. Rheumatology (Oxford, England), 1999, Volume: 38, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Anesthetics, Local; Double-Blind Method; Fasciitis; Female; Foot Dis	1999
Indomethacin or prednisolone at night in rheumatoid arthritis? Rheumatology and rehabilitation, 1978, Volume: 17, Issue:1 Topics: Adult; Aged; Analgesics; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Drug Therapy, Combination;	1978
Double-blind study of prednisolone and papase as inhibitors of complications after oral surgery. Journal of the American Dental Association (1939), 1976, Volume: 93, Issue:2 Topics: Clinical Trials as Topic; Edema; Humans; Mouth; Pain; Papain; Placebos; Postoperative Complications;	1976
A defence of the small clinical trial: evaluation of three gastroenterological studies. British medical journal (Clinical research ed.), 1986, Mar-01, Volume: 292, Issue:6520 Topics: Adult; Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Colonic Diseases, Functi	1986
Ibuprofen in rheumatoid arthritis. Clinical study of analgesic and anti-inflammatory activity. Annals of the rheumatic diseases, 1968, Volume: 27, Issue:5 Topics: Adult; Aged; Alanine Transaminase; Arthritis, Rheumatoid; Aspartate Aminotransferases; Aspirin; Doub	1968
Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. The Quarterly journal of medicine, 1968, Volume: 37, Issue:147 Topics: Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Humans; Joints; Methods; Movement; Pain; P	1968
[On the evaluation of the effect of a combination of salicylates and prednisolone in rheumatic diseases]. Arzneimittel-Forschung, 1968, Volume: 18, Issue:6 Topics: Acute Disease; Arthritis, Rheumatoid; Bone Diseases; Clinical Trials as Topic; Drug Synergism; Human	1968
Evaluation of a simple articular index for joint tenderness in rheumatoid arthritis. Annals of the rheumatic diseases, 1969, Volume: 28, Issue:2 Topics: Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Humans; Joints; Methods; Pain; Placebos; P	1969

Article	Year
Prevalence and biopsychosocial factors associated with depressive symptoms among patients living with systemic lupus erythematosus in clinical settings in urban Thailand. BMC psychiatry, 2022, 02-09, Volume: 22, Issue:1 Topics: Cross-Sectional Studies; Depression; Fatigue; Humans; Lupus Erythematosus, Systemic; Pain; Prednisol	2022
Ugeskrift for laeger, 2023, May-01, Volume: 185, Issue:18 Topics: Humans; Pain; Peripheral Nervous System Diseases; Prednisolone; Time-to-Treatment; Vasculitis	2023
Trajectories of self-reported pain-related health outcomes and longitudinal effects on medication use in rheumatoid arthritis: a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD). RMD open, 2023, Volume: 9, Issue:3 Topics: Analgesics, Opioid; Antirheumatic Agents; Arthritis, Rheumatoid; Australia; Cohort Studies; Female;	2023
Intranasal pain in a patient with Behçet's disease. BMJ (Clinical research ed.), 2020, Mar-11, Volume: 368 Topics: Antiviral Agents; Behcet Syndrome; Blister; Endoscopy; Famciclovir; Female; Glucocorticoids; Herpes	2020
Henoch-Schönlein purpura: Another COVID-19 complication. Pediatric dermatology, 2021, Volume: 38, Issue:5 Topics: Adolescent; Child; COVID-19; Humans; IgA Vasculitis; Male; Pain; Prednisolone; SARS-CoV-2	2021
Walking hyponatremia syndrome of inappropriate antidiuretic hormone secretion secondary to carbamazepine use: a case report. Journal of medical case reports, 2018, Jul-11, Volume: 12, Issue:1 Topics: Adult; Ambulatory Care; Analgesics, Non-Narcotic; Animals; Carbamazepine; Cattle; Female; Humans; Hy	2018
Oesophageal pemphigoid: a rare cause of dysphagia. Clinical journal of gastroenterology, 2019, Volume: 12, Issue:1 Topics: Anti-Inflammatory Agents; Autoantibodies; Deglutition Disorders; Desmoglein 3; Esophageal Diseases;	2019
Hunting for a cause of painful diplopia. The Medical journal of Australia, 2018, 09-01, Volume: 209, Issue:7 Topics: Aged, 80 and over; Anti-Inflammatory Agents; Diagnosis, Differential; Diplopia; Headache; Humans; Ma	2018
What Is the Optimal Dose of Predniso(lo)ne for Induction of Remission in Patients With Autoimmune Hepatitis? Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2020, Volume: 18, Issue:8 Topics: Acetaminophen; Hepatitis, Autoimmune; Humans; Pain; Prednisolone; Prednisone; Remission Induction	2020
Osteonecrosis of the femoral head in SARS patients: seven years later. European journal of orthopaedic surgery & traumatology : orthopedie traumatologie, 2013, Volume: 23, Issue:6 Topics: Adult; Bone Transplantation; Disease Progression; Female; Femur Head Necrosis; Follow-Up Studies; Gl	2013
Docetaxel chemotherapy for Chinese patients with castrate-resistant prostate cancer. Hong Kong medical journal = Xianggang yi xue za zhi, 2013, Volume: 19, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; Dis	2013
[Perception of pain in rheumatoid arthritis: relation to inflammation, psychic disorders, functional status, and quality of life]. Klinicheskaia meditsina, 2013, Volume: 91, Issue:3 Topics: Arthritis, Rheumatoid; Depression; Female; Glucocorticoids; Health Status; Humans; Inflammation; Mal	2013
Pyoderma gangrenosum - a frequently misdiagnosed skin condition. The Medical journal of Australia, 2013, Sep-16, Volume: 199, Issue:6 Topics: Diagnostic Errors; Glucocorticoids; Humans; Immunosuppressive Agents; Pain; Prednisolone; Pyoderma G	2013
[Case report of effective intravenous immunoglobulin for lower limbs pain in steroid-resistant eosinophilic granulomatosis with polyangiitis]. Rinsho shinkeigaku = Clinical neurology, 2014, Volume: 54, Issue:3 Topics: Churg-Strauss Syndrome; Drug Resistance; Female; Granulomatosis with Polyangiitis; Humans; Immunoglo	2014
Idiopathic carotidynia. VASA. Zeitschrift fur Gefasskrankheiten, 2014, Volume: 43, Issue:4 Topics: Anti-Inflammatory Agents; Carotid Artery, Common; Female; Humans; Inflammation; Magnetic Resonance I	2014
Acute exacerbation of previously undiagnosed chronic focal myositis in an Aboriginal patient on maintenance haemodialysis. BMJ case reports, 2014, Oct-23, Volume: 2014 Topics: Acute Disease; Anti-Inflammatory Agents; Biopsy; Chronic Disease; Diagnosis, Differential; Female; H	2014
Bone lymphoma revealed by cruralgia during pregnancy: a case report. The Pan African medical journal, 2014, Volume: 18 Topics: Abortion, Therapeutic; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot	2014
Successful control of radicular pain in a pediatric patient with Guillain-Barré syndrome. Brain & development, 2015, Volume: 37, Issue:9 Topics: Administration, Oral; Child; Guillain-Barre Syndrome; Humans; Male; Pain; Prednisolone; Treatment Ou	2015
Interplay between patient global assessment, pain, and fatigue and influence of other clinical disease activity measures in patients with active rheumatoid arthritis. Clinical rheumatology, 2015, Volume: 34, Issue:7 Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Denmark; Fatigue; Female; Humans; Male; Me	2015
Chronic progressive polyarthritis in a domestic shorthair cat. The Canadian veterinary journal = La revue veterinaire canadienne, 2015, Volume: 56, Issue:6 Topics: Amines; Analgesics; Animals; Anti-Inflammatory Agents; Arthritis; Buprenorphine; Cat Diseases; Cats;	2015
Oral manifestations of Crohn's disease. BMJ case reports, 2015, Oct-28, Volume: 2015 Topics: Azathioprine; Cheilitis; Crohn Disease; Glucocorticoids; Humans; Male; Oral Ulcer; Pain; Prednisolon	2015
A patient with odynophagia and unusual endoscopic findings. BMJ case reports, 2015, Nov-26, Volume: 2015 Topics: Anti-Inflammatory Agents; Deglutition Disorders; Esophageal Diseases; Esophagoscopy; Female; Glucoco	2015
Summaries for Patients. Oral Prednisolone in the Treatment of Acute Gout. Annals of internal medicine, 2016, Apr-05, Volume: 164, Issue:7 Topics: Administration, Oral; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Doubl	2016
Case of giant cell arteritis as a manifestation of immunoglobulin G4-related disease. The Journal of dermatology, 2016, Volume: 43, Issue:10 Topics: Administration, Oral; Autoimmune Diseases; Female; Forehead; Giant Cell Arteritis; Glucocorticoids;	2016
IgG4-related disease presenting with destructive sinonasal lesion mimicking malignancy. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2016, Volume: 273, Issue:11 Topics: Adult; Bone Diseases; Diagnosis, Differential; Endoscopy; Ethmoid Bone; Glucocorticoids; Headache Di	2016
Prednisolone was equivalent to indomethacin for pain reduction in acute gout. Annals of internal medicine, 2016, 05-17, Volume: 164, Issue:10 Topics: Acute Disease; Gout; Humans; Indomethacin; Pain; Prednisolone	2016
Dentin hypersensitivity-like tooth pain seen in patients receiving steroid therapy: An exploratory study. Journal of pharmacological sciences, 2016, Volume: 132, Issue:3 Topics: Adult; Dentin Sensitivity; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Pain	2016
Multisystem Langerhans Cell Histiocytosis in an Adult. The American journal of the medical sciences, 2017, Volume: 353, Issue:1 Topics: Adult; Female; Histiocytosis, Langerhans-Cell; Humans; Leukocytes, Mononuclear; Pain; Prednisolone;	2017
[Pharmacological treatment of Bell's palsy: favourable effects of prednisolone-based therapy now demonstrated]. Nederlands tijdschrift voor geneeskunde, 2008, Jun-07, Volume: 152, Issue:23 Topics: Bell Palsy; Humans; Pain; Prednisolone; Quality of Life; Treatment Outcome	2008
Prednisolone and naproxen both work for pain relief in acute gout. Medscape journal of medicine, 2008, Volume: 10, Issue:9 Topics: Anti-Inflammatory Agents; Arthritis, Gouty; Clinical Trials as Topic; Double-Blind Method; Female; H	2008
An unusual case of testicular pain. Clinical rheumatology, 2009, Volume: 28, Issue:3 Topics: Administration, Oral; Adult; Azathioprine; Diagnosis, Differential; Diuretics; Drug Therapy, Combina	2009
Case of lacrimal gland inflammation associated with ulcerative colitis. International ophthalmology, 2010, Volume: 30, Issue:1 Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Colic; Colitis, Ulcerative; Dacryocystitis; D	2010
Evaluation of prednisolone treatment in the acute phase of neuralgic amyotrophy: an observational study. Journal of neurology, neurosurgery, and psychiatry, 2009, Volume: 80, Issue:10 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brachial Plexus Neuritis; Child; Cohort Studies; Female;	2009
Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients. Scandinavian journal of rheumatology, 2009, Volume: 38, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monocl	2009
Microscopic polyangiitis initiated with liver dysfunction, calf pain and fever of unknown origin. Rheumatology international, 2010, Volume: 30, Issue:12 Topics: Administration, Oral; Antibodies, Antineutrophil Cytoplasmic; Cyclophosphamide; Dose-Response Relati	2010
Skeletal morbidity in children receiving chemotherapy for acute lymphoblastic leukaemia. Archives of disease in childhood, 2010, Volume: 95, Issue:10 Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Diseases; Child; Child	2010
Ocular masquerade syndrome as a herald of progression of acute myelogenous leukemia. Annals of hematology, 2011, Volume: 90, Issue:3 Topics: Aged; Antineoplastic Agents; Blood Transfusion; Diagnosis, Differential; Disease Progression; Fatal	2011
Lupus pernio with multiple bone cysts in the fingers. The Journal of dermatology, 2010, Volume: 37, Issue:9 Topics: Adult; Bone Cysts; Fingers; Granuloma; Humans; Male; Pain; Prednisolone; Radiography; Sarcoidosis; T	2010
[Unilateral odynophagia in rheumatoid arthritis]. Laryngo- rhino- otologie, 2011, Volume: 90, Issue:8 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cooperative Behavior; Deglutition Disorders; Diagnosis,	2011
Painful myositis in the anti-synthetase syndrome with anti-PL12 antibodies. Rheumatology international, 2012, Volume: 32, Issue:3 Topics: Acid Phosphatase; Alanine-tRNA Ligase; Autoantibodies; Cyclophosphamide; Drug Therapy, Combination;	2012
Effects of epinephrine and cortisol on the analgesic activity of metyrosine in rats. Archives of pharmacal research, 2011, Volume: 34, Issue:9 Topics: Adrenergic beta-Antagonists; alpha-Methyltyrosine; Analgesics; Animals; Carrageenan; Chromatography,	2011
Case report--progressive immobilising back and joint pain. Malawi medical journal : the journal of Medical Association of Malawi, 2011, Volume: 23, Issue:2 Topics: Adult; Ankle Joint; Anti-Inflammatory Agents; Antirheumatic Agents; Back Pain; Hip Joint; Humans; Kn	2011
Osteoporosis with underlying connective tissue disease: an unusual case. Annals of the New York Academy of Sciences, 2002, Volume: 966 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Accidental Falls; Adult; Anti-Ulcer Agents; Antibodies, Ant	2002
Bilateral panuveitis in a child with hypohidrotic ectodermal dysplasia. American journal of ophthalmology, 2002, Volume: 134, Issue:3 Topics: Child; Ectodermal Dysplasia; Epiretinal Membrane; Glucocorticoids; Humans; Hypohidrosis; Male; Pain;	2002
Mumps vaccine-associated acute orchitis with accompanying idiopathic thrombocytopenic purpura. BJU international, 2002, Volume: 90, Issue:9 Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Humans; Immunoglobulins, Intravenous; Male; M	2002
[Therapy of painful conditions of the locomotor organs by prednisolone injections]. Orvosi hetilap, 1958, Aug-31, Volume: 99, Issue:35 Topics: Humans; Injections; Joint Diseases; Pain; Prednisolone	1958
"PAINFUL LEG" FOLLOWING STROKES. The Medical journal of Australia, 1963, Nov-23, Volume: 2 Topics: Body Image; Cerebral Hemorrhage; Geriatrics; Humans; Hyaluronoglucosaminidase; Leg; Pain; Prednisolo	1963
[DIAGNOSTIC PROBLEMS IN THE CARPAL--TUNNEL SYNDROME]. Deutsche Zeitschrift fur Nervenheilkunde, 1963, Nov-07, Volume: 185 Topics: Carpal Tunnel Syndrome; Diagnosis; Female; Humans; Hydrocortisone; Injections; Median Nerve; Pain; P	1963
THE REDUCTION OF POST OPERATIVE PAIN AND EDEMA IN FOOT SURGERY THROUGH LOCAL INSTILLATION OF CORTICOSTEROIDS. Journal of the American Podiatry Association, 1964, Volume: 54 Topics: Dexamethasone; Edema; Foot; Glucocorticoids; Humans; Pain; Pain, Postoperative; Postoperative Compli	1964
AVASCULAR NECROSIS OF BONE COMPLICATING STEROID THERAPY. The British journal of radiology, 1965, Volume: 38 Topics: Cortisone; Drug Therapy; Femur Head; Joint Diseases; Necrosis; Osteonecrosis; Pain; Prednisolone; Ra	1965
Muscle involvement in a patient with Henoch-Schönlein purpura nephritis. Pediatric nephrology (Berlin, Germany), 2004, Volume: 19, Issue:2 Topics: Administration, Oral; Adolescent; Anti-Inflammatory Agents; Glomerulonephritis, Membranoproliferativ	2004
Intralesional treatment in painful rib metastases. Palliative medicine, 2004, Volume: 18, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anesthetics, Local; Anti-Inflammatory Agents; Bone Neoplasms; Humans	2004
[Therapy of painful bone metastases in patients with prostate carcinoma. The AP 32/02 Study of the AUO]. Der Urologe. Ausg. A, 2004, Volume: 43, Issue:9 Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Male; Mitoxantrone;	2004
Clinical quiz: a pediatric case presenting with fever and diffuse myalgia. Rheumatology international, 2005, Volume: 25, Issue:4 Topics: Anti-Inflammatory Agents; Child; Familial Mediterranean Fever; Female; Humans; Muscular Diseases; Pa	2005
[Tolosa-Hunt syndrome: analysis of six cases]. Arquivos de neuro-psiquiatria, 2005, Volume: 63, Issue:3A Topics: Adult; Diagnosis, Differential; Female; Follow-Up Studies; Glucocorticoids; Humans; Magnetic Resonan	2005
Prostanoids as friends, not foes: further evidence from the interference by cycloxygenase-inhibitory drugs when inducing tolerance to experimental arthritigens in rats. Inflammopharmacology, 2005, Volume: 12, Issue:5-6 Topics: Administration, Oral; Animals; Arthritis, Experimental; Aspirin; Celecoxib; Cyclooxygenase 2; Cycloo	2005
[A case of fibromyalgia treated with medical and autogenic training]. Nihon Jibiinkoka Gakkai kaiho, 2005, Volume: 108, Issue:12 Topics: Adult; Anti-Dyskinesia Agents; Anti-Inflammatory Agents; Autogenic Training; Botulinum Toxins; Combi	2005
Bortezomib-induced Sweet's syndrome. Haematologica, 2005, Volume: 90, Issue:12 Suppl Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration	2005
Still looking for the cause of fever? Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine, 2006, Volume: 8, Issue:2 Topics: Dyspnea; Fever; Glucocorticoids; Humans; Leukocytosis; Male; Middle Aged; Muscle, Skeletal; Pain; Pr	2006
Knee pain and swelling secondary to ulcerative colitis. Digestion, 2007, Volume: 75, Issue:2-3 Topics: Adult; Arthritis; Colitis, Ulcerative; Colonoscopy; Diagnosis, Differential; Fever; Glucocorticoids;	2007
An unusual complication of intra-articular injections of corticosteroids: Tachon syndrome. Two case reports. Annales de readaptation et de medecine physique : revue scientifique de la Societe francaise de reeducation fonctionnelle de readaptation et de medecine physique, 2007, Volume: 50, Issue:9 Topics: Arthralgia; Elbow Joint; Glucocorticoids; Humans; Injections, Intra-Arterial; Low Back Pain; Male; M	2007
Herpes zoster in the elderly. Geriatrics, 1967, Volume: 22, Issue:9 Topics: Adolescent; Adult; Aged; Child; Depression; Facial Paralysis; Herpes Zoster; Humans; Middle Aged; Pa	1967
Malignant mesothelioma of the pleura: clinical aspects and symptomatic treatment. European journal of respiratory diseases, 1984, Volume: 65, Issue:3 Topics: Adult; Aged; Bleomycin; Female; Fever; Humans; Male; Mesothelioma; Middle Aged; Pain; Pleura; Pleura	1984
[Pain on the right side of the neck]. Der Internist, 1983, Volume: 24, Issue:5 Topics: Adult; Diagnosis, Differential; Female; Humans; Male; Neck; Pain; Prednisolone; Thyroiditis	1983
Juxtapapillary chorioretinitis in neurosyphilis. A case report. Acta ophthalmologica, 1984, Volume: 62, Issue:3 Topics: Adult; Chorioretinitis; Eye; Fluorescein Angiography; Humans; Male; Neurosyphilis; Pain; Penicillin	1984
Pyrexia, abdominal pain and splenomegaly. The Journal of the Association of Physicians of India, 1983, Volume: 31, Issue:1 Topics: Abdomen; Adult; Anemia, Hemolytic, Autoimmune; Female; Fever; Humans; Pain; Prednisolone; Splenomega	1983
Diagnoses not to be missed: giant cell arteritis. British journal of hospital medicine, 1982, Volume: 27, Issue:4 Topics: Aged; Biopsy; Blood Sedimentation; Giant Cell Arteritis; Headache; Humans; Pain; Polymyalgia Rheumat	1982
[A case of Sweet syndrome with severe muscular pain]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1995, May-10, Volume: 84, Issue:5 Topics: Aged; Humans; Male; Muscles; Pain; Prednisolone; Sweet Syndrome	1995
Effective treatment of painful bone crises in type I gaucher's disease with high dose prednisolone. Archives of disease in childhood, 1996, Volume: 75, Issue:3 Topics: Adolescent; Adult; Anti-Inflammatory Agents; Bone Diseases; Child; Drug Therapy, Combination; Gauche	1996
Painful and painless ophthalmoplegia with cavernous sinus pseudotumour. Archives of disease in childhood, 1996, Volume: 75, Issue:3 Topics: Adolescent; Anti-Inflammatory Agents; Child; Humans; Magnetic Resonance Imaging; Male; Ophthalmopleg	1996
Glaucomatocyclitic crisis in a child. American journal of ophthalmology, 1998, Volume: 126, Issue:1 Topics: Adolescent; Clonidine; Corneal Edema; Diagnosis, Differential; Drug Therapy, Combination; Glaucoma;	1998
Commentary: low-dose high-frequency enzyme replacement therapy prevents fractures without complete suppression of painful bone crises in patients with severe juvenile onset type I Gaucher disease. Blood cells, molecules & diseases, 1998, Volume: 24, Issue:3 Topics: Adolescent; Adult; Age Factors; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Ste	1998
Calcitonin and mandibular bone resorption in systemic sclerosis. The Journal of rheumatology, 1999, Volume: 26, Issue:3 Topics: Bone Resorption; Calcitonin; Captopril; Female; Humans; Jaw; Mandible; Middle Aged; Pain; Prednisolo	1999
[Painful ischemia of the extremities with T-cell lymphoma]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1999, Volume: 50, Issue:4 Topics: Chlorambucil; Female; Foot; Hand; Humans; Ischemia; Lymphoma, T-Cell; Male; Middle Aged; Pain; Predn	1999
Oral corticosteroids and bone pain after pamidronate in adults with cystic fibrosis. Lancet (London, England), 1999, May-29, Volume: 353, Issue:9167 Topics: Adult; Anti-Infective Agents; Bone Diseases; Cystic Fibrosis; Diphosphonates; Glucocorticoids; Human	1999
Recurrent steroid-responsive trismus and painful ophthalmoplegia. Journal of the neurological sciences, 1999, Nov-15, Volume: 170, Issue:1 Topics: Anti-Inflammatory Agents; Female; Humans; Inflammation; Magnetic Resonance Imaging; Middle Aged; Oph	1999
Recurrent Tolosa-Hunt syndrome: a report of ten new cases. Cephalalgia : an international journal of headache, 1999, Volume: 19 Suppl 25 Topics: Anti-Inflammatory Agents; Brain; Cranial Nerves; Demography; Female; Humans; Inflammation; Magnetic	1999
Congenital synostosis between the scaphoid and the trapezium as a cause of tenosynovitis simulating de Quervain's disease. Chirurgie de la main, 2000, Volume: 19, Issue:3 Topics: Adult; Anti-Inflammatory Agents; Carpal Bones; Diagnosis, Differential; Female; Humans; Pain; Predni	2000
Editorial: Injecting the painful shoulder. Lancet (London, England), 1976, Jan-03, Volume: 1, Issue:7949 Topics: Adrenal Cortex Hormones; Humans; Hydrocortisone; Injections, Intra-Articular; Pain; Prednisolone; Sh	1976
Medijector--a new method of corticosteroid-anesthetic delivery. Journal of occupational medicine. : official publication of the Industrial Medical Association, 1979, Volume: 21, Issue:12 Topics: Anesthetics, Local; Dexamethasone; Drug Therapy, Combination; Glucocorticoids; Humans; Injections, J	1979
Remittent painful ophthalmoplegia: the Tolosa-Hunt syndrome? A report of seven cases and review of the literature. Journal of neurology, neurosurgery, and psychiatry, 1979, Volume: 42, Issue:3 Topics: Actinomycosis; Adolescent; Adult; Cavernous Sinus; Cerebral Angiography; Female; Granuloma; Humans;	1979
The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiation. The Journal of urology, 1979, Volume: 121, Issue:6 Topics: Chlorambucil; Drug Therapy, Combination; Estramustine; Humans; Male; Nausea; Neoplasm Metastasis; Ni	1979
Painful shoulders and painful arcs. British medical journal, 1977, Nov-12, Volume: 2, Issue:6097 Topics: Humans; Joint Diseases; Pain; Prednisolone; Shoulder; Terminology as Topic	1977
Myelomatosis. Comprehensive therapy, 1977, Volume: 3, Issue:2 Topics: Acute Kidney Injury; Alkylating Agents; Amyloidosis; Antigens, Neoplasm; Blood Viscosity; Bone and B	1977
Evaluation of analgesic agents in rats with adjuvant arthritis. Chemical & pharmaceutical bulletin, 1975, Volume: 23, Issue:6 Topics: Amphetamine; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Na	1975
[Two cases of painful ophthalmoplegic syndrome]. Rinsho shinkeigaku = Clinical neurology, 1975, Volume: 15, Issue:2 Topics: Adult; Female; Humans; Meningitis; Middle Aged; Ophthalmoplegia; Pain; Prednisolone; Sinusitis	1975
Tolosa-Hunt syndrome. The dangers of an eponym. The British journal of ophthalmology, 1975, Volume: 59, Issue:3 Topics: Aneurysm; Carotid Artery Diseases; Diagnosis, Differential; Female; Humans; Lymphoma; Male; Middle A	1975
Myalgia as the major symptom in systemic panniculitis (Weber-Christian disease). European neurology, 1992, Volume: 32, Issue:6 Topics: Adipose Tissue; Biopsy; Humans; Male; Middle Aged; Muscles; Muscular Diseases; Neurologic Examinatio	1992
[L-tryptophan-induced eosinophilia-myalgia syndrome with features of diffuse fasciitis with eosinophilia]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1990, Volume: 41, Issue:10 Topics: Eosinophilia; Fasciitis; Female; Humans; Middle Aged; Pain; Prednisolone; Tryptophan	1990
Distribution of pain provoked from lumbar facet joints and related structures during diagnostic spinal infiltration. Pain, 1989, Volume: 39, Issue:1 Topics: Back Pain; Humans; Injections, Spinal; Lidocaine; Lumbar Vertebrae; Nerve Block; Pain; Pain Measurem	1989
An unusual case of painful ophthalmoplegia in a patient with rheumatoid arthritis. Annals of ophthalmology, 1989, Volume: 21, Issue:11 Topics: Adult; Arthritis, Rheumatoid; Diplopia; Eye Movements; Female; Humans; Lupus Erythematosus, Systemic	1989
Ultrastructural features of the osteoid of patients with fibrogenesis imperfecta ossium. Bone, 1989, Volume: 10, Issue:4 Topics: Biopsy; Bone and Bones; Bone Diseases; Calcification, Physiologic; Calcitriol; Collagen; Humans; Mal	1989
Compartment syndrome as a late complication of eosinophilic fasciitis. The Journal of rheumatology, 1989, Volume: 16, Issue:10 Topics: Adult; Compartment Syndromes; Eosinophilia; Fasciitis; Humans; Leg; Male; Pain; Prednisolone; Pressu	1989
The painful thyroid. Lancet (London, England), 1986, Jun-07, Volume: 1, Issue:8493 Topics: Aspirin; Humans; Pain; Prednisolone; Thyroiditis	1986
[Strategy for using glucocorticoid preparations in neuromuscular diseases]. Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 1985, Volume: 85, Issue:11 Topics: Autoimmune Diseases; Humans; Multiple Sclerosis; Muscular Diseases; Myositis; Nerve Compression Synd	1985
Hyperalgesic properties of 15-lipoxygenase products of arachidonic acid. Proceedings of the National Academy of Sciences of the United States of America, 1986, Volume: 83, Issue:14 Topics: Animals; Arachidonate Lipoxygenases; Arachidonic Acid; Arachidonic Acids; Cyclooxygenase Inhibitors;	1986
Five patients with painless thyroiditis simultaneously developed in a nursery school. Endocrinologia japonica, 1988, Volume: 35, Issue:2 Topics: Adult; Antibodies, Viral; Female; Humans; Male; Middle Aged; Pain; Prednisolone; Schools, Nursery; T	1988
[Syndrome of perforating lateral branches of the subcostal and ilio-hypogastric nerves. An unrecognized cause of hip pain]. Revue du rhumatisme et des maladies osteo-articulaires, 1986, Volume: 53, Issue:5 Topics: Arthritis; Diagnosis, Differential; Female; Hip; Hip Joint; Humans; Lidocaine; Lumbosacral Plexus; M	1986
[Clinical picture and treatment of lesions of the epidural space in lymphosarcoma]. Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 1986, Volume: 86, Issue:6 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Daunorubi	1986
[A case of idiopathic retroperitoneal fibrosis associated with localized swelling and pain on bilateral lower legs]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1985, Volume: 74, Issue:11 Topics: Female; Humans; Leg; Middle Aged; Pain; Prednisolone; Retroperitoneal Fibrosis; Ureter	1985
Effort angina without coronary obstruction in a patient with Takayasu's aortitis: a case report. Angiology, 1985, Volume: 36, Issue:7 Topics: Adult; Angina Pectoris; Angiography; Aortitis; Coronary Disease; Electrocardiography; Female; Hemody	1985
Delayed onset of polymyalgia in polymyalgia rheumatica. British journal of rheumatology, 1986, Volume: 25, Issue:1 Topics: Aged; Blood Sedimentation; Female; Globulins; Hemoglobins; Humans; Middle Aged; Pain; Polymyalgia Rh	1986
A case of ulcerative colitis presenting as vasculitic purpura. Digestive diseases and sciences, 1985, Volume: 30, Issue:5 Topics: Barium Sulfate; Colectomy; Colitis, Ulcerative; Diarrhea; Humans; Intestinal Mucosa; Male; Middle Ag	1985
The drug therapy of ulcerative colitis and of Crohn's disease. Seminars in drug treatment, 1974,Spring, Volume: 3, Issue:4 Topics: Adrenocorticotropic Hormone; Atropine; Azathioprine; Colitis, Ulcerative; Crohn Disease; Diarrhea; D	1974
Cutaneous manifestations in capillary dilatation and endovascular fibrin deposits. Acta dermato-venereologica, 1968, Volume: 48, Issue:4 Topics: Angiomatosis; Anticoagulants; Arm; Biopsy; Blindness; Blood Coagulation Disorders; Capillaries; Chro	1968
[Combined drug therapy in highly acute attacks of pain in the course of rheumatic diseases]. MMW, Munchener medizinische Wochenschrift, 1974, Jul-05, Volume: 116, Issue:27 Topics: Acute Disease; Aminopyrine; Arthritis, Rheumatoid; Dexamethasone; Drug Combinations; Female; Humans;	1974
[Irritations of the iliosacral joint, their symptomatics and therapy]. Archiv fur orthopadische und Unfall-Chirurgie, 1970, Volume: 68, Issue:4 Topics: Acute Disease; Administration, Topical; Adolescent; Adult; Anti-Inflammatory Agents; Arthritis, Rheu	1970
Case of glomerulonephritis associated with acute toxoplasmosis. British medical journal, 1974, Sep-14, Volume: 3, Issue:5932 Topics: Acute Disease; Animals; Antigens; Biopsy; Child; Edema; Fever; Fluorescent Antibody Technique; Glome	1974
Treatment of sting ray wounds. Clinical toxicology, 1970, Volume: 3, Issue:4 Topics: Anaphylaxis; Animals; Bites and Stings; Fishes, Poisonous; Histamine H1 Antagonists; Humans; Pain; P	1970
Blood and neoplastic diseases. Myelomatosis. British medical journal, 1974, Nov-30, Volume: 4, Issue:5943 Topics: Blood Viscosity; Bone Diseases; Cyclophosphamide; Fluorides; Humans; Hypercalcemia; Melphalan; Multi	1974
[Corticoids and local anesthetics in antalgic therapy. Changes in relationship between solutions]. Minerva anestesiologica, 1973, Volume: 39, Issue:2 Topics: Adrenal Cortex Hormones; Anesthetics, Local; Drug Interactions; Humans; Hydrocortisone; Hydrogen-Ion	1973
Toad poisoning in small animals. The Veterinary record, 1973, Jun-02, Volume: 92, Issue:22 Topics: Animals; Anura; Atropine; Cat Diseases; Cats; Chloramphenicol; Dog Diseases; Dogs; Ethiopia; Female;	1973
Arthralgia and myalgia in mumps. Rheumatology and rehabilitation, 1973, Volume: 12, Issue:2 Topics: Acetaminophen; Adult; Arthritis; Blood Cell Count; Fever; Hematocrit; Hemoglobins; Humans; Male; Mum	1973
Painful ophthalmoplegia. Journal of the neurological sciences, 1970, Volume: 11, Issue:3 Topics: Acute Disease; Adolescent; Adult; Aged; Child; Chronic Disease; Cranial Nerves; Female; Functional L	1970
[Experiences with a combination of oxyphenbutazone and prednisolone in painful diseases of the locomotor system]. Medizinische Monatsschrift, 1970, Volume: 24, Issue:9 Topics: Humans; Joint Diseases; Oxyphenbutazone; Pain; Prednisolone	1970
[Indications for local corticosteroid therapy in tendopathies in athletes]. Medizinische Klinik, 1970, Jul-17, Volume: 65, Issue:29 Topics: Acetates; Achilles Tendon; Adult; Athletic Injuries; Dexamethasone; Humans; Ligaments, Articular; Ma	1970
[C.P.C. No. 150. Chief complaints: anemia, shortness of breath and right upper abdominal pain]. Naika. Internal medicine, 1969, Volume: 23, Issue:5 Topics: Abdomen; Aged; Anemia, Aplastic; Humans; Male; Pain; Peptic Ulcer; Prednisolone; Respiration	1969
Vincristine-induced neuropathy. A clinical study of fifty leukemic patients. Neurology, 1969, Volume: 19, Issue:4 Topics: Achilles Tendon; Action Potentials; Adult; Child; Child, Preschool; Cranial Nerves; Drug Synergism;	1969

prednisolone and Pain

Research Excerpts

Research

Studies (160)

Authors

Clinical Trials (9)

Trial Overview

Trial Outcomes

Part A: Number of Patients With Dose Limiting Toxicities (DLTs)

Part B: Median Best Percentage Change From Baseline in Circulating Tumour Cell (CTC) Level

Part B: Median Best Percentage Change From Baseline in Prostate Specific Antigen (PSA) Levels

Part B: Median Overall Survival (OS)

Part B: Median Radiological Progression-Free Survival (rPFS) Time

Part B: Median Time to Second Progression or Death (PFS2)

Part B: Percentage of Patients With at Least One Objective Response (Objective Response Rate [ORR])

Part B: Percentage of Patients With Progression Events or Death (rPFS)

Median Time to First Subsequent Therapy (TFST) and Median Time to Second Subsequent Therapy (TSST)

Part A Pharmacokinetics (PK): Olaparib Maximum Plasma Concentration at Steady State (Cmax,ss)

Part A Pharmacokinetics (PK): Olaparib Maximum Plasma Concentration at Steady State (Cmax,ss)

Part A PK Analysis: Olaparib Area Under the Plasma Concentration-Time Curve at Steady State (AUCss)

Part A PK Analysis: Olaparib Area Under the Plasma Concentration-Time Curve at Steady State (AUCss)

Part A PK Analysis: Olaparib Minimum Plasma Concentration at Steady State (Cmin,ss)

Part A PK Analysis: Olaparib Minimum Plasma Concentration at Steady State (Cmin,ss)

Part A PK Analysis: Olaparib Time to Reach Maximum Plasma Concentration at Steady State (Tmax,ss)

Part A PK Analysis: Olaparib Time to Reach Maximum Plasma Concentration at Steady State (Tmax,ss)

Part A PK: Abiraterone AUCss

Part A PK: Abiraterone AUCss

Part A PK: Abiraterone Cmax,ss

Part A PK: Abiraterone Cmax,ss

Part A PK: Abiraterone Cmin,ss

Part A PK: Abiraterone Cmin,ss

Part A PK: Abiraterone Tmax,ss

Part A PK: Abiraterone Tmax,ss

Part A: Percentage of Patients Experiencing Adverse Events (AEs)

Part B: Percentage of Patients Experiencing AEs

Part B: Percentage of Patients With PSA Responses

Reviews

Trials

Other Studies